Product Images Crestor

This text describes the results of a study that measured the number of events related to a primary endpoint and several secondary endpoints among two groups of subjects who received different treatments. The primary endpoint, a composite measure of several events, was experienced by more subjects in the placebo group compared to the Roswa2omg group, with a statistically significant difference. The frequencies of individual secondary endpoints, including cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization, are reported for each group, along with the corresponding hazard ratios and p-values. A footnote explains the event rate per 1000 person-years for cardiovascular death, which includes several types of fatal events and adjudicated causes of CV death.*

This document provides statistics on cumulative incidence expressed as a percentage for an unknown medical condition. The values are not specified due to the capture, and the only readable piece of information is the HR (0.56), the 95% confidence interval (0.46-0.69), and a p-value (<0.001). The bottom part shows the number of cases at risk, which is 8901 for RSV and 8801 for the placebo. The years are also shown, but the context is unclear.*

This is a description of a medication with the brand name Crestor. The medication comes in the form of round pink tablets with a dosage of 20mg. The lot number of the medication is CSRO1ZA, and it was manufactured by AstraZenec. The expiration date of the medication is 05/13. The medication should be taken as directed by a doctor or with the usual dosage information provided in the outsert. The medication comes in a container with a quantity of 30 tablets.*